Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 25Neoplasm Metastasis 5Neoplasms 3Brain Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2HER2-positive Breast Cancer 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Rectal Neoplasms 1Prostatic Neoplasms 1Patient Preference 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasm, Residual 1Melanoma 1Inflammatory Breast Neoplasms 1

Interventions

Fluorouracil 16Oxaliplatin 14Nivolumab 14Leucovorin 13pembrolizumab 9Paclitaxel 9Capecitabine 9Radiotherapy 6Radiation 6durvalumab 5Taxes 5Irinotecan 5Cisplatin 5Trastuzumab 4Specimen Handling 4Drug Therapy 4Carboplatin 4tremelimumab 3dehydroftorafur 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3Endoscopy 3Docetaxel 3Biopsy 3zimberelimab 2zanidatamab 2trastuzumab deruxtecan 2tislelizumab 2futibatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Ado-Trastuzumab Emtansine × 1 year × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡